DJIA 18,030.21 6.04 0.03%
NASDAQ 4,773.47 8.05 0.17%
S&P 500 2,081.88 -0.29 -0.01%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)

company name or ticker

Sarepta Faces Major Hurdle, and Not From Ebola

Sarepta Shares Falls on Duchenne Drug Approval Filing Delay

Why Sarepta Therapeutics Inc Stock Is Crashing Today

Shares of clinical-stage biotech Sarepta Therapeutics fell by nearly 40% this morning. Here's why.

Why I Won't Buy Ebola Stocks

The share prices of companies leading the fight against Ebola have been soaring lately. Is this investor enthusiasm justified?

Ebola: The making of a $1 billion drug

Could Sarepta Therapeutics Inc. Be Running Out of Money?

A biotech stock running out of money is a worry that healthcare investors don't take lightly. Let's take a closer look at clinical-stage drug developer Sarepta Therapeutics and discover whether or not it has enough cash in its coffers to execute on its business strategy.

Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta

New Ebola Fears in NYC Make Major Ebola Stock Waves

Some Potential Targets for Shire to Buy With $1.6B in Free Money

Ebola Stock Fallout Severe on Monday

See More Articles...